Drug intelligence / Profile preview

RK-04

Development stage: Preclinical
Lead developer: Neurodawn
Modality: Small Molecules
Administration: None

Overview

RK-04 is a preclinical-stage therapeutic candidate being developed by Myopharm for the treatment of polycystic ovarian syndrome (PCOS). According to the developer's pipeline, the drug has been associated with an orphan drug designation for this indication. While Myopharm specializes in metabolic and endocrine modulators, the specific chemical identity and mechanism of action for RK-04 remain proprietary and have not been publicly disclosed. The asset represents an early-stage expansion of Myopharm's portfolio in women's health and metabolic disorders.

Beyond the preview

Go deeper on RK-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK-04.

Explore the full profile